Citations

Clear

1315 citation(s) found for "Kyle, RA".

Electronic DNA Analysis of CSF Cell-free Tumor DNA to Quantify Multi-gene Molecular Response in Pediatric High-grade Glioma
Bruzek, Amy K., Ravi, Karthik , Muruganand, Ashwath, Wadden, Jack , Babila, Clarissa May, Cantor, Evan , Tunkle, Leo, Wierzbicki, Kyle , Stallard, Stefanie, Dickson, Robert P. , Wolfe, Ian, Mody, Rajen , Schwartz, Jonathan , Franson, Andrea , Robertson, Patricia L. , Muraszko, Karin M. , Maher, Cormac O. , Garton, Hugh , Qin, Tingtin, Franson, Andrea , Ravi, Karthik , Koschmann, Carl

Mayo Clinic

Clinical Cancer Research | October 21, 2020 | Volume: 26 | Issue: 23 | Pages: 6266-6276

10.1158/1078-0432.ccr-20-2066 | PMID 33087334 Get It

Abstract Purpose: Pediatric high-grade glioma (pHGG) diagnosis portends poor prognosis and therapeutic monitoring remains difficult. Tumors release cell-free tumor DNA (cf-tDNA) into cerebrospinal fluid (CSF), allowing for potential detection of tumor-associated mutations by CSF sampling. We hypothesized that direct, electronic analysis of cf-tDNA with a handheld platform (Oxford Nanopore MinION) could quantify patient-specific CSF cf-tDNA variant allele fraction (VAF) with improved speed and limit of detection compared with established methods. Experimental Design: We performed ultra-short fragment (100–200 bp) PCR amplification of cf-tDNA for clinically actionable alterations in CSF and tumor samples from patients with pHGG (n = 12) alongside nontumor CSF (n = 6). PCR products underwent rapid amplicon-based sequencing by Oxford Nanopore Technology (Nanopore) with quantification of VAF. Additional comparison to next-generation sequencing (NGS) and droplet digital PCR (ddPCR) was performed. Results: Nanopore demonstrated 85% sensitivity and 100% specificity in CSF samples (n = 127 replicates) with 0.1 femtomole DNA limit of detection and 12-hour results, all of which compared favorably with NGS. Multiplexed analysis provided concurrent analysis of H3.3A (H3F3A) and H3C2 (HIST1H3B) mutations in a nonbiopsied patient and results were confirmed by ddPCR. Serial CSF cf-tDNA sequencing by Nanopore demonstrated correlation of radiological response on a clinical trial, with one patient showing dramatic multi-gene molecular response that predicted long-term clinical response. Conclusions: Nanopore sequencing of ultra-short pHGG CSF cf-tDNA fragments is feasible, efficient, and sensitive with low-input samples thus overcoming many of the barriers restricting wider use of CSF cf-tDNA diagnosis and monitoring in this patient population.
Community health status and outcomes after allogeneic hematopoietic cell transplantation in the United States
Hong, Sanghee , Brazauskas, Ruta , Hebert, Kyle, Ganguly, Siddhartha , Abdel‐Azim, Hisham , Beattie, Sara , Ciurea, Stefan O. , Szwajcer, David , Badawy, Sherif M. , Gratwohl, Aloïs , LeMaistre, Charles F. , Aljurf, Mahmoud , Farhadfar, Nosha , Seo, Sachiko , Beitinjaneh, Amer , Sharma, Akshay , Law, Jason , Ulrickson, Matthew L. , Schoemans, Hélène , Černý, Jan , Rizzieri, David A. , Kamble, Rammurti T., Shaw, Bronwen E. , Khera, Nandita , Wood, William A. , Hashmi, Shahrukh K. , Hahn, Theresa , Lee, Stephanie J. , Rizzo, J. Douglas , Majhail, Navneet S. , Saber, Wael , Ciurea, Stefan O , Farhadfar, Nosha , Savani, Bipin N , Shaw, Bronwen E , Khera, Nandita , Hashmi, Shahrukh K , Majhail, Navneet S , Sharma, Akshay , Badawy, Sherif M , Lee, Stephanie J , Wood, William A , Díaz, Miguel Ángel , Olsson, Richard F. , Bhatt, Neel S. , Yared, Jean A. , Yoshimi, Ayami , Gergis, Usama , Lazarus, Hillard M. , Hashem, Hasan , Savani, Bipin N.

Mayo Clinic

Cancer | October 21, 2020 | Volume: 127 | Issue: 4 | Pages: 609-618

10.1002/cncr.33232 | PMID 33085090 Get It

BackgroundThe association of community factors and outcomes after hematopoietic cell transplantation (HCT) has not been comprehensively described. Using the County Health Rankings and Roadmaps (CHRR) and the Center for International Blood and Marrow Transplant Research (CIBMTR), this study evaluated the impact of community health status on allogeneic HCT outcomes.MethodsThis study included 18,544 adult allogeneic HCT recipients reported to the CIBMTR by 170 US centers in 2014‐2016. Sociodemographic, environmental, and community indicators were derived from the CHRR, an aggregate community risk score was created, and scores were assigned to each patient (patient community risk score [PCS]) and transplant center (center community risk score [CCS]). Higher scores indicated less healthy communities. The impact of PCS and CCS on patient outcomes after allogeneic HCT was studied.ResultsThe median age was 55 years (range, 18‐83 years). The median PCS was –0.21 (range, –1.37 to 2.10; standard deviation [SD], 0.42), and the median CCS was –0.13 (range, –1.04 to 0.96; SD, 0.40). In multivariable analyses, a higher PCS was associated with inferior survival (hazard ratio [HR] per 1 SD increase, 1.04; 99% CI, 1.00‐1.08; P = .0089). Among hematologic malignancies, a tendency toward inferior survival was observed with a higher PCS (HR, 1.04; 99% CI, 1.00‐1.08; P = .0102); a higher PCS was associated with higher nonrelapse mortality (NRM; HR, 1.08; 99% CI, 1.02‐1.15; P = .0004). CCS was not significantly associated with survival, relapse, or NRM.ConclusionsPatients residing in counties with a worse community health status have inferior survival as a result of an increased risk of NRM after allogeneic HCT. There was no association between the community health status of the transplant center location and allogeneic HCT outcomes.
Assessing the Relationship Between Institutional Cancer and Diabetes Mortality Rates Using National Death Index Data
Karlin, Nina J. , Buras, Matthew , Kosiorek, Heidi , Coppola, Kyle , Verona, Patricia M , Cook, Curtiss B. , Buras, Matthew R , Kosiorek, Heidi E , Coppola, Kyle E , Cook, Curtiss B

Mayo Clinic

Future Science OA | October 20, 2020 | Volume: 6 | Issue: 10 | Pages: No page available

10.2144/fsoa-2020-0055 | PMID 33312702 Get It

Effect of a fourth‐generation transcatheter valve enhanced skirt on paravalvular leak
Welle, Garrett A. , El‐Sabawi, Bassim , Thaden, Jeremy J. , Greason, Kevin L. , Klarich, Kyle W. , Holmes, David R. , Rihal, Charanjit S. , Eleid, Mackram F. , Alkhouli, Mohamad A, Holmes, David R , Eleid, Mackram F , Welle, Garrett A , Nkomo, Vuyisile T. , Alkhouli, Mohamad , Guerrero, Mayra , Crestanello, Juan A. , Rihal, Charanjit S.

Mayo Clinic

Catheterization and Cardiovascular Interventions | October 6, 2020 | Volume: 97 | Issue: 5 | Pages: 895-902

10.1002/ccd.29317 | PMID 33022117 Get It

AbstractObjectivesThe aim of this study was to assess the 30 day incidence of paravalvular leak (PVL) and need for aortic valve reintervention of a fourth generation balloon expandable transcatheter valve with enhanced skirt (4G‐BEV) (SAPIEN 3 Ultra) compared with a third generation balloon expandable transcatheter valve (3G‐BEV) (SAPIEN 3).BackgroundThe incidence of PVL has steadily declined with iterative improvements in transcatheter aortic valve replacement (TAVR) technology and implantation strategies.MethodsPatients who underwent TAVR at Mayo Clinic from 7/2018 to 7/2019 were included in a prospective institutional registry. 4G‐BEV has been utilized since 2/2019, and, after this date, 3G‐BEV and 4G‐BEV were simultaneously used. 4G‐BEV had three sizes (20, 23, and 26 mm) while 3G‐BEV included four sizes (20, 23, 26, and 29 mm). Both cohorts were evaluated at 30 days post‐TAVR with a transthoracic echocardiogram to assess for PVL.ResultsA total of 260 consecutive patients were included. Of these, 101 patients received a 4G‐BEV and 159 patients received a 3G‐BEV. There were more females (p = .0005) and a lower aortic valve calcium score (p = .02) in the 4G‐BEV cohort at baseline. Age, STS risk score, NYHA Class, and aortic valve mean gradient did not differ between groups. 4G‐BEV was associated with a lower incidence of mild PVL (10.8 vs. 36.5%; p < .0001) and moderate PVL (0 vs. 5.8%) compared to the 3G‐BEV at 30 days. There was no association between PVL and valve size in either cohort.ConclusionsUtilization of 4G‐BEV is associated with reduced PVL at 30 days post‐TAVR compared with 3G‐BEV.
Colon perforation in multiple myeloma patients – A complication of high‐dose steroid treatment
Vaxman, Iuliana , Kumar, Shaji , Mishra, Nitin , Dingli, David , Lacy, Martha Q. , Muchtar, Eli , Hobbs, Miriam, Fonder, Amie , Hwa, Yi L. , Kapoor, Prashant , Siddiqui, Mustaqeem , Lust, John A., Kyle, Robert A. , Hayman, Suzanne R. , Kourelis, Taxiarchis , Warsame, Rahma , Al Saleh, Abdullah S , Nitin, Mishra, Lacy, Martha, Muchtar, E , Hwa, Lisa, Visram, Alissa , Lust, John, Rajkumar, Vincent, Gertz, Morie A , Vaxman, Iuliana , Siddiqui, Mustaqeem A , Dingli, David , Saleh, Abdullah S. Al , Dispenzieri, Angela , Buadi, Francis K. , Rajkumar, S. Vincent , Leung, Nelson , Gonsalves, Wilson I. , Gertz, Morie A.

Mayo Clinic

Cancer Medicine | October 6, 2020 | Volume: 9 | Issue: 23 | Pages: 8895-8901

10.1002/cam4.3507 | PMID 33022868 Get It

Abstract Gastrointestinal complications of multiple myeloma (MM) treatment are common and include nausea, constipation, and diarrhea. However, acute gastrointestinal events like perforations are rare. We aimed to describe the characteristics and outcomes of patients with MM that had colonic perforations during their treatment. This is a retrospective study that included patients from all three Mayo Clinic sites who had MM and developed a colonic perforation. All patients were diagnosed with colonic perforations based on CT scans and were surgically treated. Patients diagnosed with AL amyloidosis, a perforated colon complicating neutropenic colitis during ASCT and those with perforation due to colonic cancer were excluded. A high dose of dexamethasone was defined as ≥40 mg dexamethasone once a week. Thirty patients met inclusion criteria. All patients received steroids at doses ≥10 mg once weekly prior to the perforation, while four (11%) were on high‐dose dexamethasone without chemotherapy. Fourteen patients were given high doses of dexamethasone. Twenty‐five patients required ostomies with all surviving surgery. Twenty‐four perforations (80%) were associated with diverticulitis. Treatment with steroids was resumed in 23 patients with no further gastrointestinal complications. The median OS was 20 months following perforation (IQR 8–59). Within the same timeframe 5854 patients were treated at Mayo Clinic for MM, making the risk of bowel perforation 0.5%. Intestinal perforations in MM are rare and, in our series, always occurred with dexamethasone ≥10 mg per week. Urgent surgery is lifesaving and resumption of anti‐myeloma treatment appears to be safe.
Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma
Abdallah, Nadine , Kapoor, Prashant , Gertz, Morie A. , Lacy, Martha Q. , Hayman, Suzanne R. , Dingli, David , Hwa, Yi L. , Fonder, Amie , Hobbs, Miriam, Lin, Yi , Kourelis, Taxiarchis , Warsame, Rahma , Siddiqui, Mustaqeem , Lust, John A., Kyle, Robert A. , Bergsagel, Leif, Greipp, Patricia T. , Kumar, Shaji , Bergsagel, P. Leif , Bergsagel, P. Leif , Gertz, Morie A , Lust, John, Greipp, Patricia, Siddiqui, Mustaqeem A , Dingli, David , Greipp, Patricia T , Lin, Yi , Baughn, Linda B. , Rajkumar, S. Vincent , Dispenzieri, Angela , Buadi, Francis K. , Go, Ronald S. , Leung, Nelson , Ketterling, Rhett P.

Mayo Clinic

Clinical Cancer Research | October 2, 2020 | Volume: 26 | Issue: 24 | Pages: 6581-6588

10.1158/1078-0432.ccr-20-2283 | PMID 33008815 Get It

Abstract Purpose: Rearrangements involving the MYC protooncogene are common in newly diagnosed multiple myeloma, but their prognostic significance is still unclear. The purpose of this study was to assess the impact of MYC rearrangement on clinical characteristics, treatment response, and survival in patients with newly diagnosed multiple myeloma. Experimental Design: This is a retrospective study including 1,342 patients seen in Mayo Clinic in Rochester, MN, from January 2006 to January 2018, who had cytogenetic testing by FISH at diagnosis, including MYC testing using the break apart FISH probe (8q24.1). Results: A rearrangement involving MYC was found in 8% of patients and was associated with elevated β2-microglobulin, ≥50% bone marrow plasma cells, IgA multiple myeloma, and the cooccurrence of trisomies. There were no differences in overall response rates between patients with and without MYC rearrangement when induction chemotherapy was proteasome inhibitor (PI)-based, immunomodulatory drug (IMiD)-based or PI + IMiD-based. Overall survival was shorter in patients with MYC rearrangement compared with patients without MYC rearrangement (5.3 vs. 8.0 years, P &lt; 0.001). MYC rearrangement was associated with increased risk of death on multivariate analysis when high-risk cytogenetic abnormalities, ISS stage III, and ≥70 years of age were included (risk ratio: 1.5; P = 0.007). Conclusions: MYC rearrangement is associated with high disease burden and is an independent adverse prognostic factor in patients with newly diagnosed multiple myeloma.
ECMO and POPH: More Help for the Right Heart
Bohman, J. Kyle , Findlay, James Y. , Krowka, Michael J. , Bohman, John K

Mayo Clinic

Liver Transplantation | September 28, 2020 | Volume: 27 | Issue: 5 | Pages: 627-628

10.1002/lt.25888 | PMID 32916765 Get It

African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States
Badar, Talha , Dávila, Omar, Fraser, Raphael , Wirk, Baldeep , Dhakal, Binod , Freytes, César O. , Valdes, Cesar Rodriguez , Vesole, David H. , Malek, Ehsan , Hildebrandt, Gerhard , Landau, Heather , Murthy, Hemant S. , Meehan, Kenneth R., Solh, Melhem , Kharfan‐Dabaja, Mohamed A. , Farhadfar, Nosha , Kamble, Rammurti T., Vij, Ravi , Munker, Reinhold , Kyle, Robert A. , Hashmi, Shahrukh K. , Ganguly, Siddhartha , Kumar, Shaji , Shah, Nina , D’Souza, Anita , Dhakal, Binod , Malek, Ehsan , Farhadfar, Nosha , Hashmi, Shahrukh K , Jagannath, Sundar , Nieto, Yago , Kumar, Shaji K , Shah, Nina , D'Souza, Anita , Murthy, Hemant S , Badar, Talha , Hari, Parameswaran , Lee, Cindy , Lazarus, Hillard M. , Berdeja, Jesús G. , Díaz, Miguel Ángel , Callander, Natalie S. , Bashir, Qaiser , Chhabra, Saurabh , Jagannath, Sundar , Nishihori, Taiga , Nieto, Yago

Mayo Clinic

Cancer | September 23, 2020 | Volume: 127 | Issue: 1 | Pages: 82-92

10.1002/cncr.33208 | PMID 32966625 Get It

BackgroundMultiple myeloma (MM) with the translocation t(11;14) may have inferior outcomes in comparison with other standard‐risk MM, and it has been suggested to portend a worse prognosis in African Americans in comparison with Whites. This study used the Center for International Blood and Marrow Transplant Research (CIBMTR) database to examine the impact of t(11;14) on the clinical outcomes of patients with MM of African American and White descent.MethodsThis study evaluated 3538 patients who underwent autologous hematopoietic cell transplantation (autoHCT) for MM from 2008 to 2016 and were reported to the CIBMTR. Patients were analyzed in 4 groups: African Americans with t(11;14) (n = 117), African Americans without t(11;14) (n = 968), Whites with t(11;14) (n = 266), and Whites without t(11;14) (n = 2187).ResultsAfrican Americans with t(11;14) were younger, had lower Karnofsky scores, and had more advanced stage MM with a higher Hematopoietic Cell Transplantation–Comorbidity Index (HCT‐CI). Fewer African Americans with t(11;14) (21%) had a coexistent high‐risk marker in comparison with Whites with t(11;14) (27%). In a multivariate analysis, race and t(11;14) had no association with progression‐free survival. However, overall survival was superior among African Americans with t(11;14) in comparison with Whites with t(11;14) (hazard ratio, 0.53; 95% confidence interval, 0.30‐0.93; P = .03). Survival was also associated with female sex, stage, time from diagnosis to transplant, a low HCT‐CI, and receipt of maintenance.ConclusionsRace may have a differential impact on the survival of patients with t(11;14) MM who undergo autoHCT and needs to be further studied.